Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 05 May 2017
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 Apr 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017.